Pfizer (PFE) Surpasses Q1 Earnings Estimates

Core Viewpoint - Pfizer reported quarterly earnings of $0.92 per share, exceeding the Zacks Consensus Estimate of $0.64 per share, and showing an increase from $0.82 per share a year ago, representing an earnings surprise of 43.75% [1][2] Financial Performance - Pfizer's revenues for the quarter ended March 2025 were $13.72 billion, which missed the Zacks Consensus Estimate by 0.88% and decreased from $14.88 billion year-over-year [2] - Over the last four quarters, Pfizer has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - Pfizer shares have declined approximately 13.1% since the beginning of the year, compared to a 6% decline in the S&P 500 [3] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.58 on revenues of $13.74 billion, and for the current fiscal year, it is $2.99 on revenues of $63.48 billion [7] - The estimate revisions trend for Pfizer is currently favorable, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Large Cap Pharmaceuticals industry, to which Pfizer belongs, is currently ranked in the top 14% of over 250 Zacks industries, suggesting a positive outlook for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]